Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Losartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.61 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Losartan SCHEMBL60 | 0.94 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL6092394 | 0.94 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL29383742 | 0.94 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL17653801 | 0.93 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL7420948 | 0.93 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL17653794 | 0.93 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL4090171 | 0.93 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL3216357 | 0.93 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL42080 | 0.93 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL4726128 | 0.93 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018002673-A1 | NOVEL FORMULATIONS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | N4 PHARMA UK LIMITED (GB) | 2018-01-04 | — | — | WO | disclosed |
| EP-1087953-B1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX SA (FR) | 2004-11-17 | — | — | EP | disclosed |
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NICOX S.A. | 2004-07-29 | — | — | US | disclosed |
| US-6645965-B1 | Sildenafil, hydralazine, minoxidil, or zaprinast; cardiovascular disorders | NICOX S.A. (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1087953-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067231-A1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX S.A. (FR) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NOS2, NOS1, NOS3 | AGTR1 13/4885AGTR2 19/4885ABCC4 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.